A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Launched by HOFFMANN-LA ROCHE · Jun 18, 2007
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-70 years of age;
- • chronic hepatitis B;
- • Hepatitis B Virus (HBV) DNA \>100,000 copies/mL.
- Exclusion Criteria:
- • previous antiviral or interferon-based therapy for chronic hepatitis B in past 6 months;
- • evidence of decompensated liver disease;
- • history or evidence of a medical condition associated with chronic liver disease other than viral hepatitis;
- • coinfection with hepatitis A, C or D, or HIV.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Novosibirsk, , Russian Federation
St Petersburg, , Russian Federation
Nizhny Novgorod, , Russian Federation
Stavropol, , Russian Federation
Samara, , Russian Federation
Irkutsk, , Russian Federation
Chelyabinsk, , Russian Federation
Ekaterinburg, , Russian Federation
Kazan, , Russian Federation
Krasnoyarsk, , Russian Federation
Novokuznetsk, , Russian Federation
Rostov Na Donu, , Russian Federation
Tomsk, , Russian Federation
Tumen, , Russian Federation
Ufa, , Russian Federation
Volgograd, , Russian Federation
Yakutsk, , Russian Federation
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials